ClinicalTrials.gov

History of Changes for Study: NCT01796171
A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)
Latest version (submitted September 2, 2019) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 19, 2013 None (earliest Version on record)
2 October 10, 2014 Contacts/Locations and Study Status
3 October 22, 2015 Contacts/Locations, Study Status, Eligibility, Study Design and Sponsor/Collaborators
4 November 12, 2015 Contacts/Locations and Study Status
5 December 22, 2015 Arms and Interventions, Study Status, Study Design, Contacts/Locations, Eligibility and Study Identification
6 January 5, 2016 Arms and Interventions, Study Description and Study Status
7 September 20, 2016 Study Status and Contacts/Locations
8 September 13, 2017 Contacts/Locations, Study Status, Arms and Interventions, Eligibility, Study Design, Study Description and Study Identification
9 April 11, 2018 Contacts/Locations, Arms and Interventions, Outcome Measures, Study Status, Oversight, Study Design, Eligibility, Conditions, Study Description and Study Identification
10 June 1, 2018 Contacts/Locations and Study Status
11 September 11, 2018 Contacts/Locations and Study Status
12 March 20, 2019 Contacts/Locations, Study Status, Eligibility and Study Design
13 May 27, 2019 Contacts/Locations and Study Status
14 September 2, 2019 Contacts/Locations and Study Status
Comparison Format:

Scroll up to access the controls

Changes (Side-by-Side) for Study: NCT01796171
June 1, 2018 (v10) -- September 11, 2018 (v11)

Changes in: Contacts/Locations and Study Status

Study Identification
Unique Protocol ID: EudraCT: 2011-000033-36 EudraCT: 2011-000033-36
Brief Title: A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)
Official Title: A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma. A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.
Secondary IDs:
Study Status
Record Verification: June 2018 September 2018
Overall Status: Recruiting Recruiting
Study Start: December 2012 December 2012
Primary Completion: June 2020 [Anticipated ] June 2020 [Anticipated ]
Study Completion: March 2025 [Anticipated ] March 2025 [Anticipated ]
First Submitted: February 19, 2013 February 19, 2013
First Submitted that
Met QC Criteria:
February 19, 2013 February 19, 2013
First Posted: February 21, 2013 [Estimate ] February 21, 2013 [Estimate ]
Last Update Submitted that
Met QC Criteria:
June 1, 2018 September 11, 2018
Last Update Posted: June 4, 2018 [Actual ] September 12, 2018 [Actual ]
Sponsor/Collaborators
Sponsor: Nordic Nanovector Nordic Nanovector
Responsible Party: Sponsor Sponsor
Collaborators: ICON Clinical Research ICON Clinical Research
Oversight
U.S. FDA-regulated Drug: Yes Yes
U.S. FDA-regulated Device: No No
Data Monitoring: Yes Yes
Study Description
Brief Summary: This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. Part B of the study will assess the efficacy and safety of two different Betalutin/lilotomab dosing regimens in adult patients with relapsed rituximab / anti-CD20-refractory follicular lymphoma who have received 2 or more prior therapies. This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. Part B of the study will assess the efficacy and safety of two different Betalutin/lilotomab dosing regimens in adult patients with relapsed rituximab / anti-CD20-refractory follicular lymphoma who have received 2 or more prior therapies.
Detailed Description:
Conditions
Conditions: Non-Hodgkin Lymphoma
Follicular Lymphoma
Non-Hodgkin Lymphoma
Follicular Lymphoma
Keywords: Radioimmunotherapy
Lu-177
Phase I study
Phase II study
Betalutin
Radioimmunotherapy
Lu-177
Phase I study
Phase II study
Betalutin
Study Design
Study Type: InterventionalInterventional
Primary Purpose: TreatmentTreatment
Study Phase: Phase 1/Phase 2Phase 1/Phase 2
Interventional Study Model: Parallel Assignment Parallel Assignment
Number of Arms: 66
Masking: None (Open Label)None (Open Label)
Allocation: RandomizedRandomized
Enrollment: 207 [Anticipated ] 207 [Anticipated ]
Arms and Interventions
Arms Assigned Interventions
Experimental: Part A, Arm 1: with lilotomab pre-dosing
Betalutin, 10 MBq/kg b.w. in escalated doses with lilotomab pre-dosing.
Drug: Betalutin
Betalutin, 10 MBq/kg b.w. in escalated doses with 40 mg lilotomab pre-dosing
Experimental: Part A, Arm 2: without pre-dosing
Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.
Drug: Betalutin
Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing
Experimental: Part A, Arm 3: with rituximab pre-dosing
Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.
Drug: Betalutin
Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing
Experimental: Part A, Arm 4: with higher dose lilotomab pre-dosing
Betalutin, 15 MBq/kg b.w. in escalated doses with a higher dose lilotomab pre-dosing regimen.
Drug: Betalutin
Betalutin, 15 MBq/kg b.w. in escalated doses with 100 mg/m2 lilotomab pre-dosing
Experimental: Part A, Arm 5: with intermediate dose lilotomab pre-dosing
Betalutin, 20 MBq/kg b.w. with an intermediate dose lilotomab pre-dosing regimen.
Drug: Betalutin
Betalutin, 20 MBq/kg b.w. in escalated doses with 60 mg/m2 lilotomab pre-dosing
Experimental: Part B
Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100mg/m2 lilotomab
Drug: Betalutin
Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100 mg/m2 lilotomab
Outcome Measures
Primary Outcome Measures:
1. Part A, Phase I
To define Maximum tolerated dose (MTD) of Betalutin Adverse events and abnormal laboratory values will be graded for toxicity according to CTCAE version 4.

[Time Frame: 12 weeks ]
Part A, Phase I
To define Maximum tolerated dose (MTD) of Betalutin Adverse events and abnormal laboratory values will be graded for toxicity according to CTCAE version 4.

[Time Frame: 12 weeks ]
2. Part A, Phase IIa
To explore tumour response rates in patients receiving Betalutin

[Time Frame: 3 months - 5 years ]
Part A, Phase IIa
To explore tumour response rates in patients receiving Betalutin

[Time Frame: 3 months - 5 years ]
3. Part B, Phase IIb
Overall response rate

[Time Frame: 3 months - 5 years ]
Part B, Phase IIb
Overall response rate

[Time Frame: 3 months - 5 years ]
Eligibility
Minimum Age: 18 Years 18 Years
Maximum Age:
Sex: All All
Gender Based:
Accepts Healthy Volunteers: NoNo
Criteria:

Part A:

Inclusion Criteria:

  • Histologically confirmed (by WHO classification) relapsed incurable non-Hodgkin B-cell lymphoma of following subtypes; follicular grade I-IIIA, marginal zone, small lymphocytic, lymphoplasmacytic, mantle cell.
  • Age ≥ 18 years
  • A pre-study WHO performance status of 0-1
  • Life expectancy should be ≥ 3 months
  • <25% tumour cells in bone marrow biopsy
  • Measurable disease by radiological methods

Exclusion Criteria:

  • Absolute Neutrophil Counts (ANC) ≤ 1.5 x 109 /l
  • Platelet count ≤ 150 x 109 /l
  • Total bilirubin ≥ 30 mmol/l
  • ALP and ALAT ≥ 4x normal level
  • Creatinine ≥ 115 µmol/l (men), 97 µmol/l (women))
  • Known CNS involvement of lymphoma
  • Previous total body irradiation
  • Known history of HAMA
  • Chemotherapy or immunotherapy received within the last 4 weeks prior to start of study treatment. Pretreatment with rituximab is allowed
  • Previous hematopoietic stem cell transplantation (autologous and allogenic)
  • Previous treatment with radioimmunotherapy
  • Receipt of live, attenuated vaccine within 30 days prior to enrolment
  • Test positive for hepatitis B (HBsAg and anti-HBc)
  • A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any excipient used in rituximab, HH1 or Betalutin

Part B:

Inclusion Criteria:

  • Histologically confirmed (by WHO classification) relapsed non-Hodgkin B-cell FL (follicular grade I-IIIA).
  • Male or female aged ≥ 18 years.
  • Received at least 2 prior chemotherapy- or immunotherapy-based regimens. Prior therapy must include a rituximab/anti-CD20 agent and alkylating agent. Prior exposure to idelalisib or other PI3K inhibitors is also allowed.
  • Patients must be refractory to the last rituximab/anti-CD20 based treatment, defined as no response (no CR or PR) during therapy or a response (CR/PR) lasting less than 6 months after the completion of a regimen of rituximab/anti-CD20 therapy (including occurrence of progressive disease (PD) during rituximab/anti-CD20 maintenance therapy, or within 6 months of completion of maintenance therapy). A previous regimen is defined as one of the following: at least 2 months of single agent therapy; at least 2 consecutive cycles of chemotherapy.
  • WHO performance status of 0-2.
  • Life expectancy of ≥ 3 months.
  • Bone marrow tumour infiltration < 25% (in biopsy taken from a site not previously irradiated).
  • Measurable disease by CT: longest diameter (LDi) > 1.5 cm for nodal lesion, LDi > cm for extra nodal lesion within 28 days prior to start of treatment.
  • ANC ≥ 1.5 x 109/L.
  • Platelet count ≥ 150 x 109/L.
  • Haemoglobin ≥ 9.0 g/dL.
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except patients with documented Gilbert's syndrome [< 3.0 mg/dL]).
  • Liver enzymes: Aspartate transaminase (AST); Alanine transaminase (ALT) or ALP ≤ 2.5 x ULN (or ≤ 5.0 x ULN with liver involvement by primary disease).
  • Adequate renal function as demonstrated by a serum creatinine < 1.5 x ULN.
  • Negative HAMA test at screening.
  • Negative test at screening for Hepatitis B (negative HBsAG and anti-HBC), Hepatitis C and HIV.

Exclusion Criteria:

  • Prior hematopoietic allogenic stem cell transplantation.
  • Prior autologous stem cell transplantation.
  • Evidence of histological transformation from FL to DLBCL at time of screening.
  • Previous total body irradiation.
  • Prior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational agent) within 4 weeks prior to start of study treatment (corticosteroid treatment at doses of ≤ 20 mg/day, topical or inhaled corticosteroids, G-CSF or GM-CSF are permitted up to 2 weeks prior to start of study treatment). Note: excludes pre-treatment with rituximab as part of this study.
  • Patients with known or suspected CNS involvement of lymphoma.
  • History of a previous treated cancer except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localised prostate cancer undergoing surveillance or surgery, localised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy, other adequately treated Stage 1 or 2 cancer currently in CR.
  • Exposure to another CD37 targeting drug.
  • A known hypersensitivity to rituximab, lilotomab, Betalutin or murine proteins or any excipient used in rituximab, lilotomab, or Betalutin.
  • Has received a live-attenuated vaccine within 30 days prior to enrolment.

Part A:

Inclusion Criteria:

  • Histologically confirmed (by WHO classification) relapsed incurable non-Hodgkin B-cell lymphoma of following subtypes; follicular grade I-IIIA, marginal zone, small lymphocytic, lymphoplasmacytic, mantle cell.
  • Age ≥ 18 years
  • A pre-study WHO performance status of 0-1
  • Life expectancy should be ≥ 3 months
  • <25% tumour cells in bone marrow biopsy
  • Measurable disease by radiological methods

Exclusion Criteria:

  • Absolute Neutrophil Counts (ANC) ≤ 1.5 x 109 /l
  • Platelet count ≤ 150 x 109 /l
  • Total bilirubin ≥ 30 mmol/l
  • ALP and ALAT ≥ 4x normal level
  • Creatinine ≥ 115 µmol/l (men), 97 µmol/l (women))
  • Known CNS involvement of lymphoma
  • Previous total body irradiation
  • Known history of HAMA
  • Chemotherapy or immunotherapy received within the last 4 weeks prior to start of study treatment. Pretreatment with rituximab is allowed
  • Previous hematopoietic stem cell transplantation (autologous and allogenic)
  • Previous treatment with radioimmunotherapy
  • Receipt of live, attenuated vaccine within 30 days prior to enrolment
  • Test positive for hepatitis B (HBsAg and anti-HBc)
  • A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any excipient used in rituximab, HH1 or Betalutin

Part B:

Inclusion Criteria:

  • Histologically confirmed (by WHO classification) relapsed non-Hodgkin B-cell FL (follicular grade I-IIIA).
  • Male or female aged ≥ 18 years.
  • Received at least 2 prior chemotherapy- or immunotherapy-based regimens. Prior therapy must include a rituximab/anti-CD20 agent and alkylating agent. Prior exposure to idelalisib or other PI3K inhibitors is also allowed.
  • Patients must be refractory to the last rituximab/anti-CD20 based treatment, defined as no response (no CR or PR) during therapy or a response (CR/PR) lasting less than 6 months after the completion of a regimen of rituximab/anti-CD20 therapy (including occurrence of progressive disease (PD) during rituximab/anti-CD20 maintenance therapy, or within 6 months of completion of maintenance therapy). A previous regimen is defined as one of the following: at least 2 months of single agent therapy; at least 2 consecutive cycles of chemotherapy.
  • WHO performance status of 0-2.
  • Life expectancy of ≥ 3 months.
  • Bone marrow tumour infiltration < 25% (in biopsy taken from a site not previously irradiated).
  • Measurable disease by CT: longest diameter (LDi) > 1.5 cm for nodal lesion, LDi > cm for extra nodal lesion within 28 days prior to start of treatment.
  • ANC ≥ 1.5 x 109/L.
  • Platelet count ≥ 150 x 109/L.
  • Haemoglobin ≥ 9.0 g/dL.
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except patients with documented Gilbert's syndrome [< 3.0 mg/dL]).
  • Liver enzymes: Aspartate transaminase (AST); Alanine transaminase (ALT) or ALP ≤ 2.5 x ULN (or ≤ 5.0 x ULN with liver involvement by primary disease).
  • Adequate renal function as demonstrated by a serum creatinine < 1.5 x ULN.
  • Negative HAMA test at screening.
  • Negative test at screening for Hepatitis B (negative HBsAG and anti-HBC), Hepatitis C and HIV.

Exclusion Criteria:

  • Prior hematopoietic allogenic stem cell transplantation.
  • Prior autologous stem cell transplantation.
  • Evidence of histological transformation from FL to DLBCL at time of screening.
  • Previous total body irradiation.
  • Prior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational agent) within 4 weeks prior to start of study treatment (corticosteroid treatment at doses of ≤ 20 mg/day, topical or inhaled corticosteroids, G-CSF or GM-CSF are permitted up to 2 weeks prior to start of study treatment). Note: excludes pre-treatment with rituximab as part of this study.
  • Patients with known or suspected CNS involvement of lymphoma.
  • History of a previous treated cancer except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localised prostate cancer undergoing surveillance or surgery, localised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy, other adequately treated Stage 1 or 2 cancer currently in CR.
  • Exposure to another CD37 targeting drug.
  • A known hypersensitivity to rituximab, lilotomab, Betalutin or murine proteins or any excipient used in rituximab, lilotomab, or Betalutin.
  • Has received a live-attenuated vaccine within 30 days prior to enrolment.
Contacts/Locations
Central Contact: Clinical Trials
Email: clinicaltrials@nordicnanovector.com
Clinical Trials
Email: clinicaltrials@nordicnanovector.com
Study Officials: Arne Kolstad, MD, PhD
Principal Investigator
Oslo University Hospital
Arne Kolstad, MD, PhD
Principal Investigator
Oslo University Hospital
Locations: United States, California
[Not yet recruiting]
Long Beach, California, United States
United States, Illinois
[Not yet recruiting]
Maywood, Illinois, United States
Australia
[Recruiting]
Hobart, Australia
AustriaAustria
[Recruiting]
Innsbruck, Austria, 6020
[Recruiting]
Innsbruck, Austria, 6020
[Recruiting]
Wien, Austria, 1090
[Recruiting]
Wien, Austria, 1090
FranceBelgium
[Not yet recruiting]
Bordeau, France
[Not yet recruiting]
Gent, Belgium
[Recruiting]
La Louvière, Belgium
[Recruiting]
Leuven, Belgium
Canada
[Not yet recruiting]
Sault Ste Marie, Canada
CroatiaCroatia
[Recruiting]
Zagreb, Croatia
[Recruiting]
Zagreb, Croatia
CzechiaCzechia
[Recruiting]
Olomouc, Czechia, 779 00
[Recruiting]
Olomouc, Czechia, 779 00
[Recruiting]
Ostrava-Poruba, Czechia, 708 52
[Recruiting]
Ostrava-Poruba, Czechia, 708 52
Finland
[Recruiting]
Helsinki, Finland
[Recruiting]
Jyväskylä, Finland
France
[Recruiting]
Bordeaux, France
France
[Not yet recruiting]
Grenoble, France
[Recruiting]
Grenoble, France
[Not yet recruiting]
Pierre-Bénite, France
[Recruiting]
Pierre-Bénite, France
[Not yet recruiting]
Tours, France
[Recruiting]
Tours, France
SpainHungary
[Recruiting]
Madrid, Spain
[Not yet recruiting]
Budapest, Hungary
IrelandIreland
[Not yet recruiting]
Dublin, Ireland
[Not yet recruiting]
Dublin, Ireland
[Not yet recruiting]
Galway, Ireland
[Not yet recruiting]
Galway, Ireland
ItalyItaly
[Not yet recruiting]
Bologna, Italy, 40138
[Recruiting]
Bologna, Italy, 40138
[Recruiting]
Firenze, Italy, 50134
[Recruiting]
Firenze, Italy, 50134
Sweden
[Recruiting]
Linköping, Sweden, 581 85
[Recruiting]
Meldola, Italy
[Recruiting]
Reggio Emilia, Italy
[Recruiting]
Borås, Sweden, 50455
[Recruiting]
Torino, Italy
NorwayNorway
[Not yet recruiting]
Bergen, Norway
[Recruiting]
Bergen, Norway
[Not yet recruiting]
Oslo, Norway, 0310
[Recruiting]
Oslo, Norway, 0310
[Not yet recruiting]
Trondheim, Norway, 7006
[Recruiting]
Trondheim, Norway, 7006
PolandPoland
[Recruiting]
Krakow, Poland, 50-510
[Recruiting]
Krakow, Poland, 50-510
[Recruiting]
Warszawa, Poland, 02-097
[Recruiting]
Warszawa, Poland, 02-097
Spain
[Recruiting]
Barcelona, Spain
[Recruiting]
Majadahonda, Spain
[Recruiting]
Ourense, Spain
Spain
[Recruiting]
Pamplona, Spain
[Recruiting]
Pamplona, Spain
[Recruiting]
Salamanca, Spain
[Recruiting]
Salamanca, Spain
[Recruiting]
Seville, Spain
[Recruiting]
Seville, Spain
[Recruiting]
Valencia, Spain, 46020
[Recruiting]
Valencia, Spain, 46020
[Recruiting]
Valencia, Spain, 46026
[Recruiting]
Valencia, Spain, 46026
SwedenSweden
[Recruiting]
Umeå, Sweden
[Recruiting]
Umeå, Sweden
TurkeyTurkey
[Recruiting]
Adana, Turkey
[Recruiting]
Adana, Turkey
[Recruiting]
Ankara, Turkey
[Recruiting]
Ankara, Turkey
[Not yet recruiting]
Ankara, Turkey
[Not yet recruiting]
Eskişehir, Turkey
[Recruiting]
Fatih, Turkey
[Recruiting]
Fatih, Turkey
[Recruiting]
İzmir, Turkey
[Recruiting]
Samsun, Turkey
[Recruiting]
Şehitkamil, Turkey
United Kingdom, DorsetUnited Kingdom, Dorset
[Recruiting]
Poole, Dorset, United Kingdom, BH15 2JB
[Recruiting]
Poole, Dorset, United Kingdom, BH15 2JB
United KingdomUnited Kingdom
[Recruiting]
Bristol, United Kingdom, BS2 8ED
[Recruiting]
Bristol, United Kingdom, BS2 8ED
[Recruiting]
Edinburgh, United Kingdom
[Recruiting]
Edinburgh, United Kingdom
[Recruiting]
Glasgow, United Kingdom, G12 0YN
[Recruiting]
Glasgow, United Kingdom, G12 0YN
[Recruiting]
Manchester, United Kingdom, M20 4BX
[Recruiting]
Manchester, United Kingdom, M20 4BX
IPDSharing
Plan to Share IPD:
References
Citations: Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95. PubMed 23267131Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95. PubMed 23267131
Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013 Mar;6(1):20-7. PubMed 23256748Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013 Mar;6(1):20-7. PubMed 23256748
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services